Axsome Therapeutics (NASDAQ:AXSM) had its price objective hoisted by HC Wainwright to $15.00 in a research report report published on Monday morning, The Fly reports. They currently have a buy rating on the stock.
A number of other analysts also recently commented on the stock. ValuEngine downgraded shares of Axsome Therapeutics from a buy rating to a hold rating in a report on Friday, December 21st. Cantor Fitzgerald set a $16.00 target price on shares of Axsome Therapeutics and gave the stock a buy rating in a report on Monday, December 10th. LADENBURG THALM/SH SH set a $5.00 target price on shares of Axsome Therapeutics and gave the stock a buy rating in a report on Wednesday, October 17th. Finally, Zacks Investment Research downgraded shares of Axsome Therapeutics from a hold rating to a sell rating in a report on Wednesday, September 12th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $24.00.
NASDAQ AXSM opened at $7.41 on Monday. The company has a debt-to-equity ratio of 6.00, a quick ratio of 1.46 and a current ratio of 1.46. Axsome Therapeutics has a 12 month low of $1.94 and a 12 month high of $9.16. The company has a market capitalization of $78.41 million, a P/E ratio of -5.98 and a beta of -0.07.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Worth Venture Partners LLC acquired a new stake in shares of Axsome Therapeutics during the third quarter valued at approximately $138,000. Sio Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 115.5% during the third quarter. Sio Capital Management LLC now owns 416,458 shares of the company’s stock valued at $1,437,000 after acquiring an additional 223,168 shares during the period. Finally, Alethea Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 102.1% during the third quarter. Alethea Capital Management LLC now owns 547,443 shares of the company’s stock valued at $1,889,000 after acquiring an additional 276,620 shares during the period. Institutional investors and hedge funds own 11.85% of the company’s stock.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Further Reading: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.